IMM 4.41% 35.5¢ immutep limited

SearchESMOMeeting CalendarESMO Virtual Plenary: Eftilagimod...

  1. 25,428 Posts.
    lightbulb Created with Sketch. 1379

    ESMO Virtual Plenary: Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma

    ESMO-Virtual-Plenary-July-2024-1000x250-AACR-date
    Start date
    11 Jul 2024
    End date
    12 Jul 2024
    Location
    Virtual Meeting
    Live on11 Jul 2024 at 18:30 CEST

    Programme

    18:30-19:30 CEST
    Welcome and introduction, Scientific background and context
    Amanda Psyrri, Attikon University Hospital, Athens, Greece

    Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from cohort B (CPS less-than 1) of the TACTI-003 study
    Robert Metcalf, The Christie NHS Foundation Trust, Manchester, UK

    Critical analysis and perspectives
    Marc Oliva, Institut Català d’Oncologia (ICO) L’Hospitalet, Barcelona, Spain

    AACR Expert Commentary
    Jong Chul Park, MGH – Massachusetts General Hospital, Boston, MA USA

    Discussion and Q&A (i)
    Faculty and online audience


 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
35.5¢
Change
0.015(4.41%)
Mkt cap ! $515.6M
Open High Low Value Volume
34.0¢ 36.0¢ 34.0¢ $1.270M 3.611M

Buyers (Bids)

No. Vol. Price($)
7 286261 35.5¢
 

Sellers (Offers)

Price($) Vol. No.
36.0¢ 253490 7
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.